CCME Global Ltd
₹ 121
3.95%
21 Jul
- close price
About
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.
Key Points
- Market Cap ₹ 548 Cr.
- Current Price ₹ 121
- High / Low ₹ 185 / 27.0
- Stock P/E
- Book Value ₹ 8.86
- Dividend Yield 0.00 %
- ROCE -2.92 %
- ROE -2.92 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 13.7 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.66% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.78 | -0.00 | -0.00 | 0.29 | 0.05 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.04 | |
| 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.75 | |
| Operating Profit | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.71 |
| OPM % | -19.23% | -68.97% | -100.00% | 95.37% | -1,775.00% | |||||||
| -0.09 | 0.42 | 0.07 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 3.67 | -0.00 | |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | 0.21 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | -0.45 | 0.35 | -0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.71 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | |
| -0.44 | 0.35 | -0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.71 | |
| EPS in Rs | -0.62 | 0.36 | -0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.16 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -120% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 75% |
| 3 Years: | 124% |
| 1 Year: | 370% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| Last Year: | -3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 45.25 |
| Reserves | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -5.18 |
| 0.17 | 0.20 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 5.24 | |
| Total Liabilities | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | 4.66 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 | |
| Total Assets | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | -0.00 | -0.00 | 5.10 | |
| 0.77 | -0.00 | -0.00 | -4.66 | 4.66 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| 4.10 | 2.62 | 0.26 | 3.00 | -0.00 | -0.00 | 0.12 | 0.12 | 0.09 | -0.00 | -0.00 | 32.25 | |
| Net Cash Flow | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | -0.00 | -0.00 | -0.01 | -0.00 | -0.00 | 37.35 |
| Free Cash Flow | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | -0.00 | -0.00 | 5.10 |
| CFO/OP | 3,240% | 3,771% | 357% | -840% | 9,380% | -10% | 100% | 100% | 64% | -0% | -0% | -718% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229.29 | 62.93 | 292.00 | -0.00 | ||||||||
| Inventory Days | -0.00 | -0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 229.29 | 62.93 | 292.00 | -0.00 | ||||||||
| Working Capital Days | 1,586.35 | 5,991.03 | 67,890.00 | 24,728.75 | ||||||||
| ROCE % | -16.62% | 6.88% | -0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% | -2.92% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Equity Shares Outstanding shares |
|
||||||||||
| Promoter Shareholding % |
|||||||||||
| Number of Shareholders count |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
15 Jul - CCME Global appoints Desai Saksena & Associates as statutory auditor and approves Rs 80,000 monthly MD remuneration from July 1, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
15 Jul - M/s Desai Saksena & Associates appointed statutory auditor; MD remuneration fixed at INR 80,000 monthly from July 1, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today Wednesday 15 July 2026
15 Jul - Board appointed Desai Saksena & Associates as statutory auditor and approved MD remuneration of ₹80,000 monthly from July 1, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jul - RTA certificate confirms Regulation 74(5) compliance for quarter ended June 30, 2026.
- Closure of Trading Window 25 Jun
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1]
a) Aquaculture Probiotic: Proteomix Protein Balanced Gel, Yuccagen Ammonia Controller, Growfast Gen Single Cell Protein, Progutgen Aquaculture Gut Probiotic, Rhodogen PS -Water Probiotic
b) Aqua Feed Supplement: Moultigen Aqua EDTA Aqua Culture, Vitagen C Aqua Culture and Zeo-Gen Multi Mineral Additive Granules from India
c) Aquaculture Water Sanitizer: Sangen- Broad Spectrum Sanitizer
d) Soil Probiotic: Genpro Wat Soil Probiotic
e) Aquaculture: Vibrio Controller In Shrimp Culture